Neglected Tropical Disease Treatment

Global Neglected Tropical Disease Treatment Market to Reach US$4.8 Billion by 2030

The global market for Neglected Tropical Disease Treatment estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. NTD Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the NTD Vaccines segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 7.0% CAGR

The Neglected Tropical Disease Treatment market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$970.2 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Neglected Tropical Disease Treatment Market – Key Trends & Drivers Summarized

Why Is Neglected Tropical Disease Treatment a Growing Global Health Priority?

Neglected Tropical Diseases (NTDs) affect over one billion people worldwide, primarily in low-income and tropical regions. These diseases, including leishmaniasis, Chagas disease, schistosomiasis, and dengue, have historically received limited attention and funding compared to other infectious diseases. However, increased global awareness and the efforts of organizations such as the World Health Organization (WHO), the Bill & Melinda Gates Foundation, and various government health agencies have propelled investment into NTD treatment and eradication programs. The growing recognition of NTDs as a major public health burden has led to expanded drug distribution initiatives, vaccine development programs, and vector control strategies. Additionally, collaborations between pharmaceutical companies, non-profit organizations, and governments have facilitated the production and distribution of cost-effective treatments, improving accessibility for affected populations. As public health policies increasingly prioritize NTD eradication, the market for treatments and preventive solutions is expected to witness significant growth.

What Are the Latest Advances in NTD Treatment and Prevention?

Research and development in NTD treatment have led to groundbreaking advancements in drug formulations, diagnostic tools, and vaccine candidates. The adoption of mass drug administration (MDA) programs, particularly for diseases such as lymphatic filariasis and soil-transmitted helminthiasis, has significantly reduced disease prevalence in endemic regions. New and repurposed drugs, including combination therapies and long-acting formulations, have improved treatment efficacy while minimizing drug resistance. Additionally, genetic and molecular research has facilitated the development of next-generation vaccines for diseases like leishmaniasis and dengue. The integration of digital health technologies, including AI-driven diagnostics and remote monitoring, has also enhanced early disease detection and treatment planning. These innovations are improving the effectiveness of NTD treatment programs, paving the way for better disease control and potential eradication.

How Are Public-Private Partnerships Driving Market Expansion?

Public-private partnerships have played a crucial role in expanding access to NTD treatments, with pharmaceutical companies collaborating with global health organizations to develop and distribute affordable medications. Many firms have implemented drug donation programs, supplying life-saving treatments to affected regions at little or no cost. Additionally, government funding and grants have incentivized research into novel therapeutics, while local healthcare infrastructure improvements have facilitated treatment delivery. The rise of telemedicine and mobile health (mHealth) initiatives has further improved outreach, enabling early diagnosis and timely intervention in remote communities. As global efforts to eliminate NTDs gain momentum, these partnerships are expected to drive significant advancements in treatment accessibility and disease management.

What Are the Key Factors Driving Growth in the Neglected Tropical Disease Treatment Market?

The growth in the neglected tropical disease treatment market is driven by several factors, including increased global health funding, advancements in drug development, and expanding public-private collaborations. The growing focus on disease eradication programs has led to significant investments in research, diagnostics, and vaccine development. The rising burden of climate change, which has expanded the geographical spread of vector-borne diseases, has further intensified the need for effective treatment solutions. Additionally, the integration of digital health technologies and AI-driven diagnostics has improved disease surveillance and treatment delivery in endemic regions. The push for universal healthcare access and the strengthening of local healthcare systems have also facilitated greater market penetration. With sustained global efforts to combat NTDs, the market for innovative and cost-effective treatment solutions is expected to expand, making significant progress toward eliminating these diseases.

SCOPE OF STUDY:

The report analyzes the Neglected Tropical Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (NTD Drugs, NTD Vaccines); Disease Type (Dengue Disease, Rabies Disease, Trachoma Disease, Buruli Ulcer Disease, Yaws Disease, Leprosy Disease, Chagas Disease, Human African Trypanosomiasis Disease, Leishmaniases Disease, Soil-Transmitted Helminthiases Disease, Other Disease Types)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Dr. Reddy`s Laboratories Ltd.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Omega Diagnostics Group PLC
• Pfizer Inc.
• Sanofi
• Shionogi & Co., Ltd.
• Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.